eGene Inc. Will Introduce the First Automated HLA SSP Genotyping System at the 2006 Annual Meeting of the American Society for Histocompatibility and Immunogenetics in San Diego, California, October 16-20, 2006.IRVINE, Calif. -- eGene Inc. (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :EGEI), developer of a revolutionary high-performance genetic analysis technology, today announced that it will introduce the first automated HLA SSP genotyping system at the 32nd annual meeting of The American Society for Histocompatibility and Immunogenetics Immunogenetics
A scientific discipline that uses immunological methods to study the inheritance of traits. Traditionally, immunogenetics has been concerned with moieties that elicit immune response, that is, with antigens (antigenic determinants). (ASHI) at the Sheraton San Diego Hotel & Marina in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation).
San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. , on October 16-20, 2006.
Ming S. Liu, CEO of eGene, made the announcement noting: "eGene's HLA SSP digital genotyping technology will benefit HLA (human leukocyte antigen human leukocyte antigen
n. Abbr. HLA
A gene product of the major histocompatibility complex; these antigens have been shown to have a strong influence on human allotransplantation, transfusions in refractory patients, and certain disease ) genotyping analysis by not only replacing labor-intensive slab gel electrophoresis methods but also simplifying and digitalizing the tedious data process work. eGene will attend this meeting to introduce our products to HLA laboratories. We will host a customer presentation and live system demonstrations during this meeting, so people can experience first-hand our automated genotyping technology. Our automated HDA-GT12 genetic analyzer has already been used by HLA lab in the City of Hope Hospital National Medical Center for more than 30,000 tests per month. There are nearly 600 HLA laboratories worldwide routinely checking the individual HLA genotype for organ and bone marrow transplantation Bone Marrow Transplantation Definition
The bone marrow—the sponge-like tissue found in the center of certain bones—contains stem cells that are the precursors of white blood cells, red blood cells, and platelets. . We believe our automatic, affordable, user-friendly genotyping system represents the future of HLA genotyping analysis."
eGene's Booth Number is 512.
ASHI (www.ashi-hla.org) is a not-for-profit association of clinical and research professionals including immunologists, geneticists, molecular biologists, transplant physicians and surgeons Physicians and surgeons are medical practitioners who treat illness and injury by prescribing medication, performing diagnostic tests and evaluations, performing surgery, and providing other medical services and advice. , pathologists and technologists. As a professional society involved in histocompatibility, immunogenetics and transplantation, ASHI is dedicated to advancing the science and application of histocompatibility and immunogenetics; providing a forum for the exchange of information; and advocating the highest standards of laboratory testing in the interest of optimal patient care.
ASHI is a member of the United Network for Organ Sharing United Network for Organ Sharing See UNOS. and has liaisons with several other scientific and medical organizations including the College of American Pathologists This article or section needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. , American Association of Blood Banks, American Association of Tissue Banks, American Society of Human Genetics, the National Marrow Donor Program The National Marrow Donor Program (NMDP) is a nonprofit organization based in Minneapolis, Minnesota, that operates the federally funded registry of volunteer hematopoietic cell donors in the United States.
These potential donors, numbering more than 6. , American Board of Transplant Coordinators, North American Transplant Coordinators Organization, American Society of Transplant Physicians, American Society of Transplant Surgeons, and the American Board of Histocompatibility and Immunogenetics.
About eGene Inc.
eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
eGene's HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP RFLP
restriction fragment length polymorphism
restriction fragment length polymorphism.
RFLP . It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The Company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.